Filtern
Volltext vorhanden
- ja (8)
Gehört zur Bibliographie
- ja (8)
Erscheinungsjahr
- 2021 (8) (entfernen)
Dokumenttyp
Sprache
- Englisch (8)
Schlagworte
- positron emission tomography (2)
- theranostics (2)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- Alzheimer’s disease (1)
- CXCR4 (1)
- GCA (1)
- MRI (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- NET (1)
- PMR (1)
- [18F]FDG PET/CT (1)
- amyloid-β (Aβ) (1)
- biomarkers (1)
- butyrylcholinesterase (1)
- carbamate (1)
- ejection fraction (1)
- enzyme kinetics (1)
- fluorine-18 (1)
- giant cell arteritis (1)
- glomerular filtration rate (1)
- inflammation (1)
- kidney (1)
- left-ventricular function (1)
- meningioma (1)
- molecular imaging (1)
- molecular medicine (1)
- nephrology (1)
- neuroblastoma (1)
- neuroendocrine neoplasms (NEN) (1)
- neuroendocrine tumors (NET) (1)
- norepinephrine transporter (1)
- polymyalgia rheumatica (1)
- prostate cancer (1)
- prostate-specific membrane antigen (PSMA) (1)
- radiotracers (1)
- renal (1)
- renal function (1)
- somatostatin receptor (SSTR) (1)
- stem cells (1)
- stem-cell research (1)
- urology (1)
- vasculature (1)
- vasculitis (1)
Institut
- Klinik und Poliklinik für Nuklearmedizin (8)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (5)
- Institut für Pharmazie und Lebensmittelchemie (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
- Medizinische Klinik und Poliklinik I (1)
- Medizinische Klinik und Poliklinik II (1)
- Pathologisches Institut (1)
We aimed to elucidate the diagnostic potential of the C-X-C motif chemokine receptor 4 (CXCR4)-directed positron emission tomography (PET) tracer \(^{68}\)Ga-Pentixafor in patients with poorly differentiated neuroendocrine carcinomas (NEC), relative to the established reference standard \(^{18}\)F-FDG PET/computed tomography (CT). In our database, we retrospectively identified 11 treatment-naïve patients with histologically proven NEC, who underwent \(^{18}\)F-FDG and CXCR4-directed PET/CT for staging and therapy planning. The images were analyzed on a per-patient and per-lesion basis and compared to immunohistochemical staining (IHC) of CXCR4 from PET-guided biopsies. \(^{68}\)Ga-Pentixafor visualized tumor lesions in 10/11 subjects, while \(^{18}\)F-FDG revealed sites of disease in all 11 patients. Although weak to moderate CXCR4 expression could be corroborated by IHC in 10/11 cases, \(^{18}\)F-FDG PET/CT detected significantly more tumor lesions (102 vs. 42; total lesions, n = 107; p < 0.001). Semi-quantitative analysis revealed markedly higher 18F-FDG uptake as compared to \(^{68}\)Ga-Pentixafor (maximum and mean standardized uptake values (SUV) and tumor-to-background ratios (TBR) of cancerous lesions, SUVmax: 12.8 ± 9.8 vs. 5.2 ± 3.7; SUVmean: 7.4 ± 5.4 vs. 3.1 ± 3.2, p < 0.001; and, TBR 7.2 ± 7.9 vs. 3.4 ± 3.0, p < 0.001). Non-invasive imaging of CXCR4 expression in NEC is inferior to the reference standard \(^{18}\)F-FDG PET/CT.